Kalipso Chalkidou

@kchalkidou

Director Global Health Policy, Senior Fellow CGD; Professor of Practice in Global Health, Imperial College; Tweets personal-RTs not endorsements

London, England
Vrijeme pridruživanja: listopad 2010.

Tweetovi

Blokirali ste korisnika/cu @kchalkidou

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @kchalkidou

  1. proslijedio/la je Tweet
    prije 4 sata

    🥁-roll please! The final blueprint is finally out -- detailing how we can kickstart an R&D revolution to sustainably serve LMIC markets with innovative 💊💉🧬 With and Adrian Towse

    Prikaži ovu nit
    Poništi
  2. proslijedio/la je Tweet

    Just spoke to the Director of the Africa CDC Dr John Nkengasong on Africa’s preparedness to deal with Corinavirus. Here’s his message to the continent.

    Prikaži ovu nit
    Poništi
  3. prije 8 sati
    Poništi
  4. prije 21 sat

    "...a strategic system of value-based tiered pricing, wherein each country pays a price for each health product commensurate with the local value it provides, could improve access, enhance efficiency, and empower countries to negotiate with manufacturers"

    Poništi
  5. proslijedio/la je Tweet
    prije 24 sata

    Too many in have an allergic reaction to "tiered" or "value-based" pricing. But if set by local value and affordability, not pharma dictates, this approach can ⬆️ affordable access to 💊. New paper with & Claxton

    Poništi
  6. 4. velj

    Work with us in London! Programme Coordinator – Global Health (London) - Center for Global Development - Career Page

    Poništi
  7. proslijedio/la je Tweet
    3. velj

    My paper with on budget credibility at county level in Kenya is out, and our blog summarizing the findings is here:

    Poništi
  8. proslijedio/la je Tweet
    3. velj

    A great example of the value of evidence based priority setting in healthcare - The use of HTA for strategic price negotiations in China led to a 60.7% average reduction of prices for new medicines and 26.4% for already listed medicines.

    Poništi
  9. 3. velj

    “not simply about driving prices to lowest possible level but that the negotiations using an evidence base of the comparative value (or cost-effectiveness) of each medicine. This underlying value of each medicine gives the purchaser (gov) an idea of price to get value for money”

    Poništi
  10. 3. velj

    “..utilization of outcome-based measures in oncology needs consensus of payers/providers..show benefits of implementing outcome measures in value based payment esp relative to implementation cost + solutions to challenges incl risk adjustment+bias control”

    Poništi
  11. proslijedio/la je Tweet
    1. velj

    Regional pooled procurements as a policy lever to increase access to health technologists .... for UHC

    Poništi
  12. 31. sij
    Poništi
  13. 31. sij
    Poništi
  14. proslijedio/la je Tweet
    30. sij

    Glad that USG is focused on response - but most of public health and experts in US are - were they not allowed to come? All hands on deck needed. cc

    Poništi
  15. 30. sij

    Drug resistant TB major cause of impoverishment across MICs.

    Poništi
  16. 30. sij

    Designing a framework for prioritising services for inclusion in South Africa's NHI "everyone has a stake in the NHI and the first group to be engaged should be South African citizens who ought to know what healthcare services they can expect under NHI"

    Poništi
  17. 30. sij

    What do MICs spend their health $ on? "The amount spent on renal replacement therapy, as a percentage of the total UHC budget, was 4.16% of $1.3bn in Indonesia, 7.7% of $1.9bn in the Philippines, and 5.1% of $5.2bn in Thailand"

    Poništi
  18. 30. sij

    "Another government official, obviously unhappy with the extent of the instructions his country received from the GFATM Secretariat, told us that “they should come and write the proposals as they have already decided on the country priorities"

    Poništi
  19. 29. sij
    Poništi
  20. 29. sij

    “while the United States represents only 15% of the global insulin market, it generates almost half of the pharmaceutical industry’s insulin revenue”

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·